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Abstract
Adenovirus and cationic liposome mediated transfer of Interleukin-10 (IL-10), a potent anti-
inflammatory cytokine, has been shown to decrease pro-inflammatory cytokine levels and overall
lung inflammation in models of lung transplantation and injury. Limitations to current approaches
of IL-10 gene therapy include poor vector delivery methods and pro-inflammatory properties of
human IL-10 under certain conditions. We hypothesize that using perfluorochemical (PFC) liquid
to deliver the highly homologous viral IL-10 (vIL-10), which is predominantly anti-inflammatory with
minimal pro-inflammatory activities, can potentially be a more effective strategy to combat
inflammatory lung diseases. In this study, we compare the use of PFC liquid versus aerosolized
method to deliver adenovirus encoding the vIL-10 gene (AdvIL-10) in C57Bl6 mice. Detectable vIL-
10 levels were measured from bronchoalveolar lavage fluid and lung homogenates at one, four, ten
and thirty days after AdvIL-10. Furthermore, we determined if use of PFC liquid could allow for the
use of a lower dose of AdvIL-10 by comparing the levels of detectable vIL-10 at different doses of
AdvIL-10 delivered +/- PFC liquid. Results showed that PFC liquid enhanced detectable vIL-10 by
up to ten fold and that PFC liquid allowed the use of ten-fold less vector. PFC liquid increased
detectable vIL-10 in lung homogenates at all time points; however, the increase in detectable vIL-
10 in BAL fluid peaked at four days and was no longer evident by thirty days after intratracheal
instillation. In summary, this is the first report utilizing PFC liquid to enhance the delivery of a
potentially therapeutic molecule, vIL-10. We believe this strategy can be used to perform future
studies on the use of the predominantly anti-inflammatory vIL-10 to treat inflammatory lung
diseases.
Background
Interleukin-10 (IL-10) is a predominantly anti-inflamma-
tory cytokine secreted by activated macrophages, lym-
phocytes and other cells involved in regulation of the
immune response. Some of the known pathways regu-
lated by IL-10 include modulation of Jak/STAT signaling,
suppression of TH1 T-cell differentiation, and inhibition
of macrophage production of pro-inflammatory cytokines
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[1-6]. Since its discovery over a decade ago, many studies
have investigated the potential use of IL-10 to treat
inflammatory diseases ranging from arthritis to sepsis.
One area of research that shows promise is the use of gene
transfer-mediated IL-10 expression in the treatment of
lung inflammatory diseases. IL-10 gene therapy has been
successful at preserving lung integrity and curtailing an
over-exuberant inflammatory response in murine lung
pneumonia and systemic inflammation models [7-10].
Furthermore, inflammatory and immune-mediated lung
injury, including obliterative bronchiolitis, remains a
major cause of morbidity and mortality for lung trans-
plant recipients. Recombinant adenovirus vector medi-
ated IL-10 expression in lung epithelium was successful at
reducing obliterative bronchiolitis in an experimental het-
erotopic rat lung transplant model[11].
However, both human and murine IL-10 can also have
pro-inflammatory action under certain conditions. In
contrast, the highly homologous viral IL-10 derived from
Epstein-Barr virus BCRF-1 protein is predominantly anti-
inflammatory with minimal pro-inflammatory activities;
therefore, vIL-10 is potentially a better candidate than
human IL-10 (hIL-10) for treating inflammatory diseases
[12-14]. For this reason, our studies were conducted with
vIL-10 instead of human or mouse IL-10.
Feasibility of IL-10 gene therapy for lung diseases hinges
on developing an effective delivery system and likely com-
partmental expression restricted to the lung. Due to the
short half-life of IL-10, strategies utilizing recombinant IL-
10 protein require many repeated doses and makes long-
term administration impractical. To circumvent this prob-
lem, gene therapy strategies remain appealing. Previous
studies have used lipid carriers to enhance plasmid medi-
ated IL-10 delivery with limited success[10]. Many other
groups have reported using viral vectors to deliver IL-10
with greater success, but still likely have not identified the
most effective method of delivery. Furthermore, these
studies often used large amounts of adenovirus vectors
raising concerns for adenovirus-associated toxicity. In
response to these concerns, recent studies using other
recombinant vectors to deliver IL-10 to lung epithelium
have been reported. For example, recombinant sendai
virus has been used to successfully improve IL-10 gene
delivery to treat a murine model of bronchial fibrous
obliterans after tracheal transplantation[15]. Developing
a strategy to boost IL-10 delivery to the lung may be ben-
eficial in future experimental lung injury research and suc-
cessful lung gene therapy in humans.
We have developed a method to enhance adenovirus
delivery by utilizing perfluorochemical (PFC) liquid[16].
PFC liquids have been safely used in liquid ventilation tri-
als in humans and various experimental animal models
[17-24]. We have used PFC liquids to improve adenovirus
and adeno-associated virus delivery in rodents and non-
human primates[16,25,26]. Previously, our studies have
been limited to delivery of the reporter gene beta-galactos-
idase. With the current investigation, we sought to deter-
mine the effectiveness of utilizing PFC liquid to deliver a
potentially beneficial biologically active gene, vIL-10, in
AdvIL-10.
Methods
Adenovirus viral IL-10 construction
Recombinant type 2 E1a/E1b deleted, replication defi-
cient, adenovirus carrying the viral IL-10 gene driven by
the CMV promoter was kindly provided by Dr. Jay Kolls
(Louisiana State University). This construct is designated
as AdvIL-10 for this report.
AdvIL-10 transduction of lung epithelial cells
A549 transformed human lung epithelial cells (American
Type Culture Collection®, Manassas, VA) were cultured in
DMEM media containing fetal bovine serum 10%
(HyClone®, Logan, UT), L-glutamine 1% (Bio-Whittaker,
Walkersville, MD) and Penicillin 2% (Bio-Whittaker,
Walkersville, MD). A549 cells were incubated in a humid-
ified 37°C incubator with 21% oxygen and 5% carbon
dioxide. Cultures were grown in tissue-culture twelve-well
plates (Nunc™) until cells were 70–80% confluent. A mul-
tiplicity of infection (MOI) of 1000:1 of AdvIL-10 was
used to transduce the A549 cells. Supernatant was col-
lected and stored at -80°C.
Vector and PFC Liquid Instillation
All animal studies were approved by the IACUC of the
Fred Hutchinson Cancer Research Center and conformed
to AAALAC and institutional IACUC standards. Male 6–8
week old C57Bl/6 mice (Charles River, Wilmington, MA)
were housed and fed ad libitum in accordance to institu-
tional animal use protocols. Mice weighed 19–24 grams
at the time of the procedure. The procedure for adminis-
tration of vector and PFC liquid by transtracheal puncture
has been described in detail16. In brief, mice were anesthe-
tized with an intraperitoneal injection of Avertin (tribro-
moethanol and tertiary amyl alcohol) 1 mg/kg and
immobilized in supine position with head elevated 30°.
Supplemental 100% oxygen was given at 5–10 liters per
minute to the nares for the duration of the procedure. The
skin was prepped with 70% ethanol and the trachea was
exposed by cut-down with a scalpel and blunt dissection.
The strap muscles overlying the trachea were carefully
spread to expose the trachea. A 0.5 mL 27 gauge insulin
syringe (Becton-Dickinson, Franklin Lakes, NJ) was used
to deliver 50 μL of either AdvIL-10 or Adlac-z at the
desired concentration by puncturing the trachea just
below the larynx and instilling the vector over 1–2 min-
utes. PFC liquid (Perfluoro-chemical FC-75®, ACROSJournal of Inflammation 2007, 4:9 http://www.journal-inflammation.com/content/4/1/9
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Organics, Fisher Scientific, Fairlawn, NJ) was pre-oxygen-
ated by bubbling 100% oxygen through a 23 gauge needle
submerged in 5–10 mL of PFC liquid for 2 minutes.
Immediately following vector administration, PFC liquid
was instilled with a 1 ml syringe and 25 gauge needle at a
dose of 10 mL/kg body weight (190 μL to 240 μL) through
the same puncture site used the deliver the adenovirus
vector. Aerosolized vector delivery was performed by
delivering 10 mL/kg body weight of air following vector
instillation. The incision was sutured closed with 2-0 silk
in an interrupted fashion. Mice were recovered under a
heat lamp in an oxygenated cage until fully awake and
active. Mice were observed daily for illness. Overall mor-
tality rate was 8%.
Lung Harvest and Analyses
Bronchoalveolar Lavage
At the designated times after vector administration,
treated mice (n = 3–5) along with naïve control mice (n =
3) were euthanized with an over an overdose of Avertin
and immobilized in a supine position. The heart-lung
block was exposed by cut-down technique and a blunted
23-gauge butterfly needle inserted into the trachea and
secured with 2-0 silk ligature. The lungs were lavaged with
1 mL PBS containing 0.6 mM EDTA and protease inhibi-
tor cocktail (PMSF 1 mM, leupeptin 1 μg/mL, aprotinin 2
ng/mL) using a 3 mL syringe. The lavage was repeated one
time. Total cell counts were obtained using a hemacytom-
eter and cell differentials determined on cytospin prepara-
tions by DiffQuick™ (International Reagent Corp., Kobe,
Japan) staining. Total protein levels were measured with
the BCA protein assay (Pierce, Rockford, IL).
Determination of vIL-10 content in BAL fluid and lung homogenates
After performing BAL, the right lower lobe was removed
and snap frozen in liquid nitrogen and stored at -80°C.
The right lower lobe was homogenized in 1 cc sterile fil-
tered lysis buffer (NaCl, KCl, Triton-X-100 2%, Tris-HCl 1
mM, PMSF, leupeptin, aprotinin, and pH 7.4). Debris was
removed by centrifuging lung homogenate at 13,000 g for
10 minutes at 4°C. The supernatant was decanted and
stored at -80°C.
IL-10 ELISA
IL-10 levels in the BAL fluid and lung homogenate were
measured with a human IL-10 ELISA kit specific for
human and viral IL-10 protein according to manufac-
turer's instructions (Immunotech, Marseille, France).
Importantly, the IL-10 ELISA kit did not detect mouse IL-
10.
Statistics
Results of IL-10 ELISA and cell counts were analyzed using
unpaired student t-test. Statistical significance was consid-
ered as a p-value less than 0.05.
Results
AdvIL-10 Mediated Viral IL-10 Expression In A549 Lung 
Epithelial Cells
Viral IL-10 levels were measured from cell culture media
after AdvIL-10 administration at 1000:1 MOI. Viral IL-10
was readily detectable by ELISA. The detectable levels of
viral IL-10 was nearly two times greater when the culture
medium was treated with protease inhibitor cocktail
(1,600 ng/ml) compared to culture media collected with-
out protease inhibitor cocktail (780 ng/ml) (Fig 1).
Hence, the remaining experiments were performed in the
presence of protease inhibitor cocktail in the collection
medium.
PFC Liquid Increases Detectable IL-10
To determine the effect of PFC liquid on AdvIL-10 deliv-
ery, C57 mice were instilled with 1 × 109 particles of
AdvIL-10 with and without PFC liquid. Viral IL-10 levels
were measured in BAL fluid at one, four, ten and thirty
days after intratracheal instillation, and the levels were
compared to reflect the level of viral IL-10 transgene
expression. The ELISA kit used to measure viral IL-10 lev-
els was specific for viral IL-10 or human IL-10 and did not
detect endogenous murine IL-10. Viral IL-10 levels were
significantly higher in the mice receiving AdvIL-10 with
PFC liquid versus AdvIL-10 with air (Fig. 2a). The largest
difference in viral IL-10 levels, a five-fold increase, was
detected in BAL fluid collected four days after intratra-
cheal AdvIL-10 delivery. The difference was no longer
appreciated at thirty days. In contrast, vIL-10 levels meas-
ured from right lower lobe lung homogenates in the
AdvIL-10 + PFC group were approximately two-fold
higher than the AdvIL-10 + air group at each time point
(Fig. 2b). Although the overall boost in detectable vIL-10
AdvIL-10 infects lung A549 epithelial cells to produce detect- able vIL-10 protein in the culture media and addition of pro- tease inhibitor cocktail preserves detectable vIL-10 Figure 1
AdvIL-10 infects lung A549 epithelial cells to produce 
detectable vIL-10 protein in the culture media and 
addition of protease inhibitor cocktail preserves 
detectable vIL-10. A549 cells at were infected with 1000:1 
MOI of either Adlac-Z or AdvIL-10. Supernatants collected 
+/- protease inhibitor cocktail and assayed for vIL-10 by 
ELISA. Values represent average of two experiments.
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was lower when measured in lung homogenates com-
pared to BAL fluid measurements, the increase in vIL-10
levels was statistically significant at all time points and
persisted to the longest measured time point of thirty
days.
PFC Liquid Permits A Lower Dose Of AdvIL-10
We sought to determine if PFC liquid could allow the use
of a lower dose of AdvIL-10. We delivered a ten-fold lower
dose of AdvIL-10, 1 × 108 particles per animal, and com-
pared the detectable IL-10 levels obtained with an
AdvIL10 dose of 1 × 109 particles per animal. Use of PFC
liquid to deliver a ten-times lower dose of AdvIL-10 (1 ×
108 particles/animal) showed similar detectable IL-10 lev-
els in the BAL fluid when compared to a ten-fold higher
dose of AdvIL-10 (1 × 109 particles/animal) instilled with-
out PFC liquid when measured at four days after vector
instillation, the time of peak vIL-10 expression (Fig. 3).
PFC Liquid Did Not Increase Lung Inflammation Provoked 
by the Adenovirus Vector
Previous experience with PFC liquid in animal models
demonstrated a pro-inflammatory effect of PFC liquid in
the lung. We measured the cell count and cell differential
from the BAL fluid collected at one and four days after
PFC liquid administration (Fig. 4). Total cell counts from
PFC liquid allows for use of a lower dose of AdvIL-10 Figure 3
PFC liquid allows for use of a lower dose of AdvIL-10. 
BAL fluid viral IL-10 levels fluid from mice treated with lower 
dose 1 × 108 particles of AdvIL-10 with PFC liquid (≡), lower 
dose 1 × 108 particles AdvIL-10 with air (), or higher dose 
1 × 109 particles AdvIL-10 with air (■). Control animals did 
not receive AdvIL-10. Values represent mean ± SEM (* p-
value < 0.05 when compared with lower dose 1 × 108 parti-
cles AdvIL-10 alone group, n = 4 per group).
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Use of PFC liquid increases detectable viral IL-10 in BAL fluid (A) and lung homogenate (B) Figure 2
Use of PFC liquid increases detectable viral IL-10 in BAL fluid (A) and lung homogenate (B). Viral IL-10 levels 
from BAL fluid or right lower lobe lung homogenate were collected at 1, 4, 10 and 30 days after intratracheal instillation of 
AdvIL-10 with PFC liquid (■) or AdvIL-10 with air (●). Each time point represents the mean ± SEM (* p-value < 0.05). Repre-
sentative experiments from repeated experiments (n = 3–5/group).
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BAL fluid collected one day after mice received intratra-
cheal instillation of AdvIL-10 with PFC liquid (375,000
cells/mL) and AdvIL-10 with air (325,000 cells/mL) were
not statistically different. Both values were statistically
higher than the control total cell count of (275,000 cells/
ml). Similar results were obtained from BAL fluid total
cell counts obtained four days after intratracheal instilla-
tion. The cell differential one day after vector +/- PFC liq-
uid instillation showed a significant increase in
neutrophil count in both the AdvIL-10 + PFC liquid group
and the AdvIL-10 group (53% macraphages, 44% neu-
trophils, 3% lymphocytes versus 55% macrophages, 44%
neutrophils, 1% lymphocytes, respectively) as compared
to the naïve control animals (98% macrophages, 0.4%
neutrophils, 2% lymphocytes). By day four the cell differ-
ential in both AdvIL-10 groups returned to baseline values
with a prdominance of marcrophages greater than 92%
and neutrophils less than 6%.
Discussion
In this study, we have demonstrated that use of PFC liquid
enhances intratracheal delivery of recombinant AdvIL-10
to rodent lung. Use of PFC liquid increased the amount of
detectable vIL-10 by up to five fold. Furthermore, PFC liq-
uid decreased AdvIL-10 dose by ten-fold to achieve similar
results as AdvIL-10 delivered with air. This is the first
report demonstrating the feasibility of delivering a poten-
tially biologically therapeutic gene utilizing PFC liquid in
animals.
We demonstrated a disparity in the kinetics of measurable
vIL-10 from BAL fluid and lung homogenate samples.
PFC liquid increased detectable vIL-10 levels from BAL
fluid, but the boost from PFC liquid diminished over
time, eventually showing no difference from the non-PFC
group by day thirty. In contrast, vIL-10 levels measured
from lung homogenates showed a steady difference in
detectable vIL10 at all time points, extending to the long-
est measured time points of thirty days. This data suggests
that detectable vIL-10 levels vary depending on the com-
partment that it is measured. Our findings are consistent
with prior reports indicating that vIL-10 transgene expres-
sion can be measured for an extended period time in lung
tissue, with the longest reported time period extending
Use of PFC liquid does not potentiate transient lung inflammation provoked by adenovirus delivery Figure 4
Use of PFC liquid does not potentiate transient lung inflammation provoked by adenovirus delivery. (A) Total 
cell count from BAL fluid collected 1 day after intratracheal instillation of AdvIL-10 with PFC liquid or AdvIL-10 with air. (B) 
Cell differential ( %macrophage, ≡ %neutrophil, ■ %lymphocyte) from BAL fluid collected at 1 day after intratracheal delivery 
of AdvIL-10 with PFC liquid or AdvIL-10 with air. (C) Total cell count from BAL fluid collected 4 days after intratracheal instil-
lation of AdvIL-10 with PFC liquid or AdvIL-10 with air. (D) Cell differential ( %macrophage, ≡ %neutrophil, ■ %lymphocyte) 
from BAL fluid collected at 4 days after intratracheal delivery of AdvIL-10 with PFC liquid or AdvIL-10 with air. Control animals 
did not receive adenovirus instillation. Values represent mean ± SEM.
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beyond 42 days after intratracheal instillation[7,27]. The
diminished detectable secreted vIL-10 in the BAL fluid
despite increased intracellular vIL-10, suggests that over
time, secreted vIL-10 is either degraded more rapidly in
the extracellular environment or the secretion of vIL-10 is
decreased. Rather than increased systemic expression,
localized over expression of vIL-10 may in fact be more
beneficial. In murine models of sepsis, compartmental
delivery of IL-10 has been shown to be beneficial, whereas
systemic delivery showed no protection from
lethality[28]. Moreover, other IL-10 studies in murine
sepsis suggest systemic over-expression of IL-10 may be
deleterious due to its potential to create a state of immune
paralysis by producing a TH2 state and suppressing TH1
cytokine production[29,30]. Therefore, developing an
efficient method for over-expressing IL-10 localized to the
lung could prove to be critical in a successful strategy to
combat lung inflammatory diseases such as ARDS and
transplant rejection.
The mechanism of how PFC liquid improves transgene
expression is still unclear. The first assumption is that PFC
liquid acts as a carrier to allow for improved distribution
of adenovirus throughout the lung. Although we believe
this may be true, PFC liquid appears to have more activity
than a mere inert carrier. Previously, we have demon-
strated that PFC liquid transiently opens tight junctions,
which in turn, may allow adenovirus to gain better access
to its receptors on the basolateral surface of epithelial
cells[31]. Furthermore, nebulized PFC liquid up to one
hour prior to adenovirus delivery appears to enhance
transgene expression (unpublished data from our labora-
tory).
The use of PFC liquid allows for an increase in detectable
IL-10 and can be potentially beneficial for applications of
curbing lung inflammation. One area of particular interest
is to use PFC liquid to deliver AdvIL-10 to the donor lung
to improve lung function and graft survival. Several ani-
mal models have successfully demonstrated the potential
benefits of pre-conditioning the donor lung to over-
express IL-10 [32-35]. We hope the use of PFC liquid will
aid future studies aimed at evaluating the potential use of
vIL-10 in treating inflammatory lung disease.
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